-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The innovation system of the Science and Technology Innovation Board has set up diverse and inclusive listing standards.
The fifth set of listing standards allows unprofitable companies to list.
At the beginning of its introduction, this standard was considered to be a tailor-made listing standard for unprofitable biopharmaceutical companies
.
According to the data, 38 of the 417 companies listed on the Science and Technology Innovation Board have not yet made a profit at the time of their IPO
.
Among these 38 unprofitable listed companies, 25 share prices have broken, of which 16 have broken more than 30%, and 5 biopharmaceutical companies have broken more than 50%
.
In addition, according to the sorting announcement, BeiGene will have a large loss in 2021, with a net profit loss of 9.
747 billion yuan
.
However, BeiGene’s product cooperation revenue in 2021 is as high as $543 million
.
It is reported that BeiGene currently has three approved drugs researched and developed in its own laboratory, including Baiyueze (a Bruton tyrosine kinase (hereinafter referred to as "BTK") used to treat various blood tumors) small-molecule inhibitor), Baixian (tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumors and hematological tumors) and Baixian (pamiparib, an anti-PD-1 antibody immunotherapy) a selective small molecule inhibitor of PARP1 and PARP2)
.
BeiGene has been approved to list Baiyaze in the United States, China, the European Union, the United Kingdom, Canada, Australia and other international markets, and in China Baizean (Tislelizumab) and Baihuize (Pamirpa) profit)
.
Analysts said that behind the bearish market capital is the commercialization problem of biopharmaceutical companies
.
Such as China Cell, Maiwei Bio, Zejing Pharmaceutical, Frontier Bio, and Dizhe Medical's five innovative pharmaceutical companies have increased their continued losses in 2021
.
Regarding the reasons for the continuous increase in the scale of losses, the five companies have similar statements, all of which are that the products under development are in the R&D stage and have not yet been commercialized, the payment of equity incentive fees has increased, and the continuous investment of funds for clinical trials has led to an increase in R&D expenses, etc.
.
Among them, China Cell stated that during the reporting period, the company's self-developed product Ancaine (SCT800, recombinant human coagulation factor VIII) was approved for listing in July 2021, and began to generate sales revenue continuously.
As of the end of the reporting period, the total operating income was 13,439.
28 million, a substantial increase over the same period last year
.
However, the company's loss has also increased, mainly because the company has a large number of products under development and many products are undergoing Phase II/III clinical studies for different indications.
R&D expenses continued to increase during the period
.
In addition, with the listing of Ancain, in order to further expand market share and increase market penetration, the company's market sales team is still growing, and the corresponding market sales expenses such as personnel salaries and promotion fees have also increased simultaneously
.
It is worth noting that CanSino has become a biopharmaceutical company that has achieved "U" (Note: "U" after the stock on the Science and Technology Innovation Board means that the listed company has not yet made a profit)
.
In 2021, CanSino achieved a year-on-year increase of 171 times in operating income to 4.
3 billion yuan; net profit attributable to the parent after deductions increased by 4.
5 times year-on-year to 1.
797 billion yuan, compared with a loss of 511 million yuan in the previous year
.
However, analysts said that CanSino's turnaround is somewhat accidental
.
The company has not developed an innovative vaccine
.
It is understood that as of the end of 2021, CanSino's recombinant Ebola virus disease vaccine (adenovirus vector) has completed new drug registration, two meningococcal vaccine products have obtained drug registration certificates, and the remaining vaccines are in the clinical trial stage and are newly registered.
The extent to which completed vaccine products will contribute to revenue remains uncertain
.
The research report of Haitong Securities also pointed out that there are still major changes in CanSino’s performance in 2022-24
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The fifth set of listing standards allows unprofitable companies to list.
At the beginning of its introduction, this standard was considered to be a tailor-made listing standard for unprofitable biopharmaceutical companies
.
According to the data, 38 of the 417 companies listed on the Science and Technology Innovation Board have not yet made a profit at the time of their IPO
.
Among these 38 unprofitable listed companies, 25 share prices have broken, of which 16 have broken more than 30%, and 5 biopharmaceutical companies have broken more than 50%
.
In addition, according to the sorting announcement, BeiGene will have a large loss in 2021, with a net profit loss of 9.
747 billion yuan
.
However, BeiGene’s product cooperation revenue in 2021 is as high as $543 million
.
It is reported that BeiGene currently has three approved drugs researched and developed in its own laboratory, including Baiyueze (a Bruton tyrosine kinase (hereinafter referred to as "BTK") used to treat various blood tumors) small-molecule inhibitor), Baixian (tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumors and hematological tumors) and Baixian (pamiparib, an anti-PD-1 antibody immunotherapy) a selective small molecule inhibitor of PARP1 and PARP2)
.
BeiGene has been approved to list Baiyaze in the United States, China, the European Union, the United Kingdom, Canada, Australia and other international markets, and in China Baizean (Tislelizumab) and Baihuize (Pamirpa) profit)
.
Analysts said that behind the bearish market capital is the commercialization problem of biopharmaceutical companies
.
Such as China Cell, Maiwei Bio, Zejing Pharmaceutical, Frontier Bio, and Dizhe Medical's five innovative pharmaceutical companies have increased their continued losses in 2021
.
Regarding the reasons for the continuous increase in the scale of losses, the five companies have similar statements, all of which are that the products under development are in the R&D stage and have not yet been commercialized, the payment of equity incentive fees has increased, and the continuous investment of funds for clinical trials has led to an increase in R&D expenses, etc.
.
Among them, China Cell stated that during the reporting period, the company's self-developed product Ancaine (SCT800, recombinant human coagulation factor VIII) was approved for listing in July 2021, and began to generate sales revenue continuously.
As of the end of the reporting period, the total operating income was 13,439.
28 million, a substantial increase over the same period last year
.
However, the company's loss has also increased, mainly because the company has a large number of products under development and many products are undergoing Phase II/III clinical studies for different indications.
R&D expenses continued to increase during the period
.
In addition, with the listing of Ancain, in order to further expand market share and increase market penetration, the company's market sales team is still growing, and the corresponding market sales expenses such as personnel salaries and promotion fees have also increased simultaneously
.
It is worth noting that CanSino has become a biopharmaceutical company that has achieved "U" (Note: "U" after the stock on the Science and Technology Innovation Board means that the listed company has not yet made a profit)
.
In 2021, CanSino achieved a year-on-year increase of 171 times in operating income to 4.
3 billion yuan; net profit attributable to the parent after deductions increased by 4.
5 times year-on-year to 1.
797 billion yuan, compared with a loss of 511 million yuan in the previous year
.
However, analysts said that CanSino's turnaround is somewhat accidental
.
The company has not developed an innovative vaccine
.
It is understood that as of the end of 2021, CanSino's recombinant Ebola virus disease vaccine (adenovirus vector) has completed new drug registration, two meningococcal vaccine products have obtained drug registration certificates, and the remaining vaccines are in the clinical trial stage and are newly registered.
The extent to which completed vaccine products will contribute to revenue remains uncertain
.
The research report of Haitong Securities also pointed out that there are still major changes in CanSino’s performance in 2022-24
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
